An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients

BACKGROUND: The progression of COVID-19 has different clinical presentations, which raises a number of immunological questions. OBJECTIVES: This study aimed to investigate MMP-9 and TIMP-1 levels in patients diagnosed with COVID-19 and whether the MMP-9/TIMP-1 ratio is associated with lung involveme...

Descripción completa

Detalles Bibliográficos
Autores principales: Demir, Nazlim Aktug, Kirik, Sema Yilmaz, Sumer, Sua, Ural, Onur, Kiratlı, Hatice Esranur, Vatansev, Husamettin, Hayatsal, Esra Paydas, Arslan, Ugur, Cebeci, Hakan, Demir, Lutfi Saltuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Makerere Medical School 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398462/
https://www.ncbi.nlm.nih.gov/pubmed/37545954
http://dx.doi.org/10.4314/ahs.v23i1.5
_version_ 1785084063324831744
author Demir, Nazlim Aktug
Kirik, Sema Yilmaz
Sumer, Sua
Ural, Onur
Kiratlı, Hatice Esranur
Vatansev, Husamettin
Hayatsal, Esra Paydas
Arslan, Ugur
Cebeci, Hakan
Demir, Lutfi Saltuk
author_facet Demir, Nazlim Aktug
Kirik, Sema Yilmaz
Sumer, Sua
Ural, Onur
Kiratlı, Hatice Esranur
Vatansev, Husamettin
Hayatsal, Esra Paydas
Arslan, Ugur
Cebeci, Hakan
Demir, Lutfi Saltuk
author_sort Demir, Nazlim Aktug
collection PubMed
description BACKGROUND: The progression of COVID-19 has different clinical presentations, which raises a number of immunological questions. OBJECTIVES: This study aimed to investigate MMP-9 and TIMP-1 levels in patients diagnosed with COVID-19 and whether the MMP-9/TIMP-1 ratio is associated with lung involvement in COVID-19. METHODS: This study was conducted with 192 patients and 45 healthy controls. ELISA was used to measure the MMP-9 and TIMP-1. RESULTS: The MMP-9 and TIMP-1 levels of the patients were found to be higher than those of the controls. MMP-9 and TIMP-1 were detected more in patients with lung involvement on chest CT scans than in those with no lung involvement on chest CT scans. A comparison of lung involvement levels revealed no difference was found between the groups. The MMP-9/TIMP-1 ratio was 5.8 in the group with lung involvement on chest CT scans and 6.1 in the group without lung involvement on chest CT scans. No difference was found between the two groups. A comparison with respect to lung involvement levels showed that the MMP-9/TIMP-1 ratio difference was found between the groups. CONCLUSION: Diagnostic and treatment methods targeting MMP-9 activity or neutrophil activation may be important in predicting lung involvement in COVID-19 and directing clinical outcomes.
format Online
Article
Text
id pubmed-10398462
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Makerere Medical School
record_format MEDLINE/PubMed
spelling pubmed-103984622023-08-04 An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients Demir, Nazlim Aktug Kirik, Sema Yilmaz Sumer, Sua Ural, Onur Kiratlı, Hatice Esranur Vatansev, Husamettin Hayatsal, Esra Paydas Arslan, Ugur Cebeci, Hakan Demir, Lutfi Saltuk Afr Health Sci Articles BACKGROUND: The progression of COVID-19 has different clinical presentations, which raises a number of immunological questions. OBJECTIVES: This study aimed to investigate MMP-9 and TIMP-1 levels in patients diagnosed with COVID-19 and whether the MMP-9/TIMP-1 ratio is associated with lung involvement in COVID-19. METHODS: This study was conducted with 192 patients and 45 healthy controls. ELISA was used to measure the MMP-9 and TIMP-1. RESULTS: The MMP-9 and TIMP-1 levels of the patients were found to be higher than those of the controls. MMP-9 and TIMP-1 were detected more in patients with lung involvement on chest CT scans than in those with no lung involvement on chest CT scans. A comparison of lung involvement levels revealed no difference was found between the groups. The MMP-9/TIMP-1 ratio was 5.8 in the group with lung involvement on chest CT scans and 6.1 in the group without lung involvement on chest CT scans. No difference was found between the two groups. A comparison with respect to lung involvement levels showed that the MMP-9/TIMP-1 ratio difference was found between the groups. CONCLUSION: Diagnostic and treatment methods targeting MMP-9 activity or neutrophil activation may be important in predicting lung involvement in COVID-19 and directing clinical outcomes. Makerere Medical School 2023-03 /pmc/articles/PMC10398462/ /pubmed/37545954 http://dx.doi.org/10.4314/ahs.v23i1.5 Text en © 2023 Demir NA et al. https://creativecommons.org/licenses/by/4.0/Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Demir, Nazlim Aktug
Kirik, Sema Yilmaz
Sumer, Sua
Ural, Onur
Kiratlı, Hatice Esranur
Vatansev, Husamettin
Hayatsal, Esra Paydas
Arslan, Ugur
Cebeci, Hakan
Demir, Lutfi Saltuk
An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients
title An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients
title_full An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients
title_fullStr An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients
title_full_unstemmed An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients
title_short An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients
title_sort evaluation of matrix metalloproteinase-9 (mmp-9) and tissue inhibitor metalloproteinase-1 (timp-1) serum levels and the mmp-9/timp-1 ratio in covid-19 patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398462/
https://www.ncbi.nlm.nih.gov/pubmed/37545954
http://dx.doi.org/10.4314/ahs.v23i1.5
work_keys_str_mv AT demirnazlimaktug anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT kiriksemayilmaz anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT sumersua anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT uralonur anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT kiratlıhaticeesranur anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT vatansevhusamettin anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT hayatsalesrapaydas anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT arslanugur anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT cebecihakan anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT demirlutfisaltuk anevaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT demirnazlimaktug evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT kiriksemayilmaz evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT sumersua evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT uralonur evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT kiratlıhaticeesranur evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT vatansevhusamettin evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT hayatsalesrapaydas evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT arslanugur evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT cebecihakan evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients
AT demirlutfisaltuk evaluationofmatrixmetalloproteinase9mmp9andtissueinhibitormetalloproteinase1timp1serumlevelsandthemmp9timp1ratioincovid19patients